Form D · Biotechnology
Mach5 Therapeutics, Inc.
Atlanta, GA · CIK 0002018014
Offering snapshot reported Nov 4, 2024 · SEC filing
- Reported sold
- $19.2M Offering amount: $19.9M
- Investors reported
- 15 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 24, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 4, 2024 | Initial | $19,179,509 | No comparison | 15 | SEC filing |
| Apr 17, 2024 | Amendment | $4,175,000 | $1,500,004vs Apr 3, 2024 | 7 | SEC filing |
| Apr 3, 2024 | Initial | $2,674,996 | No comparison | 6 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-528600
Source: Form D, filed Nov 4, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Patrick J. Crutcher | Director, Executive |
| Justin Di Martino | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
650 Ponce De Leon Ave Ste. 300 #2347
Atlanta, GA, 30308
Atlanta, GA, 30308